Preanalgesic Effect of Gabapentin in Total Knee Repair

This study is currently recruiting participants.

Verified by Texas Health Resources, January 2006

First Received: January 16, 2006 Last Updated: February 27, 2007 History of Changes

Sponsor:	Texas Health Resources
Information provided by:	Texas Health Resources
ClinicalTrials.gov Identifier:	NCT00279487

Purpose

The purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.

Condition	Intervention
Pain	Drug: Gabapentin

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Placebo Control, Single Group Assignment

Resource links provided by NLM:

Drug Information available for: Gabapentin

U.S. FDA Resources

Further study details as provided by Texas Health Resources:

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients undergoing total knee replacement who received pain management by the following modality:
- Intravenous patient-controlled analgesia (IV-PCA) opioid
- Local femoral nerve block with 1.5% mepivacaine 20 ml and 0.5% ropivacaine 20 ml

Exclusion Criteria:

Age < 18 years old

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279487

Contacts

Contact: Rob Hutchison, PharmD

214-345-2493

robhutchison@texashealth.org

Locations

United States, Texas
Presbyterian Hospital of Dallas	Recruiting
Dallas, Texas, United States, 75231
Contact: Rob Hutchison 214-345-2493 robhutchison@texashealth.org
Contact: Denise Stamos 214-345-2966 denisestamos@texashealth.org
Principal Investigator: William Tucker
Sub-Investigator: Jeffrey Pirinelli
Sub-Investigator: Joy Aguwa

Sponsors and Collaborators

Texas Health Resources

Investigators

Principal Investigator:

Rob Hutchison

Texas Health Resources

More Information

No publications provided

Study ID Numbers:	P768
Study First Received:	January 16, 2006
Last Updated:	February 27, 2007
ClinicalTrials.gov Identifier:	NCT00279487 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Texas Health Resources:

Patients undergoing total knee replacement who received pain management by the following modality:
IV PCA opioid
Local femoral nerve block with 1.5% Mepivacaine & 0.5% Ropivacaine

Additional relevant MeSH terms:

Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Gabapentin
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antiparkinson Agents
Calcium Channel Blockers
Excitatory Amino Acid Agents
Cardiovascular Agents

Antimanic Agents
Pharmacologic Actions
Membrane Transport Modulators
Sensory System Agents
Therapeutic Uses
Anti-Anxiety Agents
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Anticonvulsants
Excitatory Amino Acid Antagonists

ClinicalTrials.gov processed this record on November 27, 2009